3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
11
Phase 1
10
Phase 1/2
4
Phase 3
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Inflammatory Breast Neoplasms
1
Fallopian Tube Neoplasms
1
Epstein-Barr Virus Infections
1
Endometrial Adenocarcinoma
1
Cystadenocarcinoma, Serous
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Carcinoma In Situ
1
Biliary Tract Neoplasms
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Adenocarcinoma Of Esophagus
1
Interventions
Gemcitabine
5
Capecitabine
4
pembrolizumab
3
Fluorouracil
3
Cisplatin
3
vinflunine
2
enzalutamide
2
cabazitaxel
2
abiraterone
2
Ipilimumab
2
Haloperidol
2
Androgen Antagonists
2
vedolizumab
1
trifluridine tipiracil drug combination
1
relugolix
1
racemetyrosine
1
nimotuzumab
1
nilutamide
1
lanreotide
1
histrelin
1
futibatinib
1
exemestane
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
bicalutamide
1
beta-Glucans
1
auricularum
1
atezolizumab
1
apatinib
1
apalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Neoplasm Metastasis
×
Taxes
×
Clear all
NCT06783140
2025-12-05
PLATINUM-CAN
University Health Network, Toronto
Phase 2/3
Recruiting
10 enrolled